Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

129 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
gp100(209-2M) peptide immunization of human lymphocyte antigen-A2+ stage I-III melanoma patients induces significant increase in antigen-specific effector and long-term memory CD8+ T cells.
Walker EB, Haley D, Miller W, Floyd K, Wisner KP, Sanjuan N, Maecker H, Romero P, Hu HM, Alvord WG, Smith JW 2nd, Fox BA, Urba WJ. Walker EB, et al. Among authors: alvord wg. Clin Cancer Res. 2004 Jan 15;10(2):668-80. doi: 10.1158/1078-0432.ccr-0095-03. Clin Cancer Res. 2004. PMID: 14760090
Adjuvant immunization of HLA-A2-positive melanoma patients with a modified gp100 peptide induces peptide-specific CD8+ T-cell responses.
Smith JW 2nd, Walker EB, Fox BA, Haley D, Wisner KP, Doran T, Fisher B, Justice L, Wood W, Vetto J, Maecker H, Dols A, Meijer S, Hu HM, Romero P, Alvord WG, Urba WJ. Smith JW 2nd, et al. Among authors: alvord wg. J Clin Oncol. 2003 Apr 15;21(8):1562-73. doi: 10.1200/JCO.2003.09.020. J Clin Oncol. 2003. PMID: 12697882 Clinical Trial.
Vaccination of women with metastatic breast cancer, using a costimulatory gene (CD80)-modified, HLA-A2-matched, allogeneic, breast cancer cell line: clinical and immunological results.
Dols A, Smith JW 2nd, Meijer SL, Fox BA, Hu HM, Walker E, Rosenheim S, Moudgil T, Doran T, Wood W, Seligman M, Alvord WG, Schoof D, Urba WJ. Dols A, et al. Among authors: alvord wg. Hum Gene Ther. 2003 Jul 20;14(11):1117-23. doi: 10.1089/104303403322124828. Hum Gene Ther. 2003. PMID: 12885350 Clinical Trial.
Immune effects of escalating doses of granulocyte-macrophage colony-stimulating factor added to a fixed, low-dose, inpatient interleukin-2 regimen: a randomized phase I trial in patients with metastatic melanoma and renal cell carcinoma.
Smith II JW, Kurt RA, Baher AG, Denman S, Justice L, Doran T, Gilbert M, Alvord WG, Urba WJ. Smith II JW, et al. Among authors: alvord wg. J Immunother. 2003 Mar-Apr;26(2):130-8. doi: 10.1097/00002371-200303000-00005. J Immunother. 2003. PMID: 12616104 Clinical Trial.
129 results